Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

QBW-276

Phase Two

Phase Two

Therapeutic Approach

Mucociliary Clearance

QBW276 is a compound designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance. 

Status

A phase two study to test the safety, tolerability and effectiveness of QBW276 in people with CF is underway.

Sponsor

This program is sponsored by Novartis Pharmaceuticals. It is being conducted through the Therapeutics Development Network.



Contact us about QBW-276 >